EGFR and non-small cell lung carcinoma: The JO25567 and NEJ026 [13] reported that the OS and PFS in A + T therapy were prolonged and recommended combined erlotinib and bevacizumab as a first-line regimen in EGFR mutation-positive NSCLC [26, 27].